Company Overview

Novo Nordisk A/S is a global healthcare company focused on the discovery, development, manufacturing, and commercialization of pharmaceutical products. The company operates primarily within the pharmaceuticals and biotechnology industries, with a longstanding specialization in treatments for diabetes, obesity, and rare chronic diseases. Its core revenue is driven by injectable and oral therapies addressing metabolic and endocrine disorders, particularly GLP-1–based therapies, insulin products, and biopharmaceutical treatments for hemophilia and growth disorders.

Founded in 1923 in Denmark, Novo Nordisk emerged from early insulin production and evolved into one of the world’s largest diabetes-focused drug manufacturers. Over the decades, the company expanded its therapeutic focus to obesity and rare diseases, while maintaining a vertically integrated business model encompassing research, development, manufacturing, and global distribution. Novo Nordisk is publicly listed in Denmark and trades in the U.S. through American Depositary Receipts, including the OTC ticker NONOF.

Business Operations

Novo Nordisk organizes its activities primarily around Diabetes and Obesity Care and Rare Disease business segments, which collectively account for the vast majority of company revenue. The Diabetes and Obesity Care segment includes insulin products, GLP-1 receptor agonists, and combination therapies, while the Rare Disease segment focuses on treatments for hemophilia, growth hormone deficiencies, and other serious endocrine and hematologic conditions.

The company operates a fully integrated value chain, controlling proprietary research platforms, biologics manufacturing facilities, and global supply infrastructure. Manufacturing and R&D assets are concentrated in Denmark, the United States, and select international locations. Novo Nordisk conducts sales and marketing activities in more than 80 countries, supported by a mix of wholly owned subsidiaries and regional commercial organizations.

Strategic Position & Investments

Novo Nordisk’s strategy emphasizes sustained growth in metabolic diseases, with obesity positioned as a major long-term growth driver alongside diabetes. The company continues to invest heavily in next-generation GLP-1–based therapies, combination treatments, and lifecycle management of its existing product portfolio. Significant capital investments have been directed toward expanding manufacturing capacity for biologics to support rising global demand.

Strategically, Novo Nordisk has pursued targeted acquisitions, licensing agreements, and internal pipeline development rather than large-scale conglomerate mergers. Its investments include expanded production facilities in North America and Europe, as well as early-stage research in cardiometabolic diseases and adjacent therapeutic areas. The company also maintains a controlling ownership structure through the Novo Nordisk Foundation, which supports long-term investment horizons and research funding.

Geographic Footprint

Novo Nordisk is headquartered in Denmark and maintains a strong operational presence across North America, Europe, Asia-Pacific, Latin America, and parts of Africa. The United States represents its single largest market by revenue, particularly for diabetes and obesity therapies, followed by key European and emerging markets.

Manufacturing and R&D operations are geographically diversified, with major production sites in Denmark, the United States, France, China, and Brazil. Commercial subsidiaries and affiliates support regional market access, regulatory engagement, and localized supply chains, giving the company a broad international footprint and resilience against single-market dependency.

Leadership & Governance

Novo Nordisk operates under a governance model designed to balance commercial performance with long-term societal and scientific goals. Strategic oversight is influenced by its ownership structure, with the Novo Nordisk Foundation holding controlling voting power. Leadership emphasizes patient-centric innovation, long-term value creation, and sustainability in healthcare delivery.

Key executives include:

• Lars Fruergaard Jørgensen – President and Chief Executive Officer
• Karsten Munk Knudsen – Executive Vice President and Chief Financial Officer
• Marcus Schindler – Executive Vice President, Research & Early Development
• Ludovic Helfgott – Executive Vice President, Product & Portfolio Strategy
• Anna Windle – Executive Vice President, Commercial Strategy & Corporate Affairs